Physician profile
Sakura Kinjo
NPI 1598721425
$2,681.49
in general payments reported to CMS, 2019-2025
11 companies · $450 in 2025
The $450 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2021: $42.76 · 2022: $1,679 · 2023: $265 · 2024: $103 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $817.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $1,604.99 | 2022-2025 | Iovera, Exparel |
| Vertex Pharmaceuticals Incorporated | $246.41 | 2025 | |
| Heron Therapeutics, INC. | $202.21 | 2022-2024 | Zynrelef, Aponvie |
| Masimo Corporation | $166.90 | 2022 | |
| Pajunk Medical Systems, LP | $142.36 | 2019 | |
| Chiesi USA, INC. | $120.53 | 2023 | Cleviprex |
| Fresenius Kabi USA, LLC | $67.73 | 2022 | |
| Acacia Pharma INC | $42.76 | 2021 | |
| Eagle Pharmaceuticals, INC. | $39.85 | 2023 | |
| Avanos Medical | $29.11 | 2023 | On-Q* Pump and Accessories |
| Merck Sharp & Dohme LLC | $18.64 | 2024 | Bridion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sakura Kinjo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.